1	
2	
3	
4	Safety and efficacy of orally administered full-spectrum medicinal cannabis plant
5	extract 0.08% THC (NTI-164) in children with autism spectrum disorder:
6	An open-label study
7	
8	
9	Dima El-Sukkari ¹ , Kanan Sharma ¹ , Bobbi Fleiss ² , Dion L. Braganza ¹ , Alison Crichton ^{3,4,}
10	Michael C. Fahey ^{1*}
11	
12	¹ Monash Children's Hospital, Clayton, Victoria, Australia
13	^{2.} RMIT University, STEM College, Bundoora, Victoria, Australia
14	³ Department of Paediatrics, Monash University,
15	⁴ Developmental Paediatrics, Department of Paediatrics, Monash Children's Hospital
16	
17	*Corresponding author
18	E-mail: Michael.Fahey@monash.edu
19	
20	
21	Funding This study was supported by Fenix Innovations.
22	
23	
24	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 Abstract

Autism spectrum disorder (ASD) is commonly associated with debilitating comorbidities impacting the well-being of affected children and their families. Some children with ASD experience behavioural difficulties that do not respond well to current medications and may also experience unwanted side effects. Therefore, it is crucial to develop alternative, safe and effective therapies. The improved understanding of the endocannabinoid system, together with emerging evidence for the therapeutic effects of cannabis derivatives in neurodevelopment disorders, has led to an exploration of their use in ASD.

This open-label study assessed the efficacy and safety of a novel oil-based fullspectrum medicinal cannabis plant extract 0.08% THC (NTI-164) in treating 14 children with ASD symptoms (13.4 years, range 10-17). Data on the safety profile of NTI-164 was collected through biochemical analysis, vital signs, and parent and participant reports. The efficacy was assessed through a dose-escalation protocol using a broad range of validated clinical behavioural assessments and parent and child-reported questionnaires.

Following four weeks of treatment with NTI-164, 93% of participants demonstrated significant overall improvement in ASD-related symptoms compared to baseline with transient side effects that did not interfere with their general functioning. In addition, targeted behavioural problems were rated as much improved or very much improved in 46% of the treated patients. More than half of caregivers and children also reported decreased anxiety symptoms.

The findings from this study suggest that NTI-164 is well-tolerated and safe, with potential clinical benefits in improving disruptive behaviours and reducing anxiety in children with ASD-related symptoms. Future longitudinal and well-controlled studies are warranted to develop evidence-based clinical therapies and further evaluate the therapeutic benefit of full-

49 spectrum cannabis extracts in managing ASD core and associated comorbid symptoms in this50 group of children.

51 Trial registration number ACTRN12621000760875

- 52
- 53

54 Introduction

Autism Spectrum Disorder (ASD) is a group of pervasive neurodevelopmental disorders 55 that appear in early childhood. These disorders are characterised by social functioning deficits, 56 restricted or repeated patterns of behaviour across the lifespan [1], and other comorbidities such 57 as intellectual disabilities, epilepsy, anxiety, hyperactivity, irritability, and sleep disturbances. [2, 58 3] These symptoms can significantly impact a person's daily functioning. [4, 5] Globally, the 59 prevalence of ASD is estimated to range from 0.4% to 1.7% [6]. In the last decade, the 60 prevalence rate of young children (under five years) diagnosed with ASD has increased by 61 6.7%, from 2.7 million in 1990 to 2.9 million in 2019 [7]. 62

The families of children with ASD face a substantial financial burden, with recent 63 global estimates indicating 2834 EUR total costs for health-related services combined with 64 indirect societal costs over two months [8]. The estimated lifetime social cost in the US alone 65 was \$7 trillion for the last three decades (1990-2019) and is forecasted to increase to \$11-15 66 trillion in the following decade [9]. The continuing rise in ASD prevalence is further projected 67 to generate an enormous economic burden on US healthcare for decades and to reach an annual 68 cost estimate of \$5.54 trillion by 2060, with substantial potential yearly savings of \$1.9 trillion 69 through ASD prevention strategies [10]. Despite thorough investigation, no evidence supports 70 the effectiveness of pharmacological treatments in relieving some of the symptoms that cause 71 people with ASD distress. [11, 12]. However, these pharmacological treatments often result in 72

adverse side effects in children, with a notable variation in effectiveness between individuals
[13] and a lack of adherence [14]. The complexity of the ASD behavioural phenotype and its
aetiology resulting from the interaction of multiple genetic and environmental risk factors
further limits targeted interventions and the development of effective therapies [15, 16].
Therefore, to address core behaviours and co-morbid symptoms associated with ASD, targeted
therapeutic interventions are urgently needed.

The endocannabinoid system (ECS), consisting of cannabinoid receptors (CB1 and 79 CB2), endocannabinoids (endogenous bioactive ligands) and metabolic enzymes [17] presents 80 as a potential pharmacological target for developing therapeutics in the management of ASD 81 82 symptoms since it has a crucial role in modulation of neuronal plasticity during development [18] and associated with social-emotional processes [19] which are impaired in ASD-related 83 phenotypes [20, 21]. The central endocannabinoid receptors CB1 and CB2 are expressed 84 85 mainly in sensory neurons and immune cells, including microglia [17]. The endogenous cannabinoids are produced as required, activating presynaptic receptors to reduce calcium 86 87 uptake and inhibit the release of neurotransmitters, consequently influencing a broad range of biological responses [22]. Alterations in ECS functionality have been reported in several 88 89 preclinical ASD models [23-25] and clinical studies [26-28], suggesting that ASD pathogenesis 90 likely involves dysregulation of the endocannabinoid signalling pathway. These findings suggest that endocannabinoid anandamide (AEA) and its associated metabolic enzymes may 91 be a potential therapeutic target for ASD-related behavioural impairment. In animal studies, 92 treatment with inhibitors of the enzyme fatty acid amide hydrolase that degrades anandamide 93 resulted in increased AEA levels, restoring cognitive and social deficits in the ASD-related 94 knockout models [29-31]. 95

96 The increased understanding of the ECS signalling concurrent with growing evidence
97 for the therapeutic effects of cannabis (*Cannabis sativa* L.) in neurodevelopment disorders has

been the catalyst for extensive research on the two most abundant active constituents $\Delta 9$ -98 Tetrahydrocannabinol (THC) and Cannabidiol (CBD). During the last two decades, there has 99 been a surge in clinical trials of CBD owing to the absence of psychoactive effects and its 100 confirmed favourable safety profile in humans for the treatment of several neurological and 101 psychiatric disorders [32-34]. In addition, accumulating evidence from experimental and 102 animal model studies on the effect of CBD has demonstrated modulation of a broad range of 103 biological responses, including antidepressant [35], anti-inflammatory [36], antinociceptive 104 [37], anti-seizure [38], immunomodulatory [39] and neuroprotective activities [40]. 105 106 Cannabinoids are generally well-tolerated, but evidence suggests that the risk of hepatotoxicity may be increased when combined with other medications. This risk is usually low, dose-107 dependent, and more likely to occur in individuals with a history of liver disease.[41] Rigorous 108 109 controlled clinical studies are needed to determine the efficacy and safety profile of cannabinoids in children. 110

111 There is growing evidence that using CBD in combination with other plant compounds found in cannabis as a full-spectrum botanical medicine could provide unique therapeutic 112 benefits, as suggested by anecdotal reports and emerging research in the field. [42] This effect, 113 known as the entourage effect, was initially proposed as a regulatory mechanism for the 114 endocannabinoid system, whereby multiple compounds enhance the activity of endogenous 115 cannabinoids. A recent meta-analysis of observational studies showed that twice as many 116 patients with treatment-resistant epilepsy improved when treated with an herbal formulation 117 that offered a better safety profile than isolated CBD product [46]. Furthermore, promising 118 119 evidence from preclinical cancer models supports the potential for the entourage effect of botanical preparations to produce enhanced therapeutic responses than individual cannabinoids 120 [47-49]. Given that the current single molecule approach of individual phytocannabinoids 121 remains the predominant pharmaceutical development strategy [50], for complex diseases such 122

as ASD, multi-target strategies and botanical drug development may be an effective treatmentstrategy.

Evidence from animal studies suggests that CBD positively affects various physiological responses. However, there is limited evidence from clinical trials to support the potential therapeutic benefits of this non-psychoactive phytocannabinoid for pediatric neurodevelopmental disorders [51]. Only three randomised controlled studies have been published on medicinal cannabis use in children with ASD; two were short-term [58, 59], and the other only reported sleep outcomes [60]. Additionally, most studies on this topic are openlabel observational or retrospective design [52-57].

This single centre, phase I/II open-label study aimed to evaluate the efficacy and safety of a novel oil-based full-spectrum medicinal cannabis plant extract with 0.08% THC (NTI-134 164) in children with ASD over four weeks of daily treatment.

135

136

137 Materials and methods

138

139 Study design and participants

The study design was a single-centre open-label trial to evaluate the safety and efficacy of a novel full-spectrum medicinal cannabis plant extract containing only 0.08% THC (NTIlabel 164) in children with ASD over four weeks of daily treatment. The trial enrolled 18 eligible male and female paediatric patients aged 8-17 with Level 2 or 3 ASD based on the Autism

Diagnostic Observational Schedule (ADOS-2) criteria [61] between 4 February 2022 and 8
September 2022.

This study was approved by the Monash Health Human Research Ethics Committee (RES-21-0000-177A) and registered with the Australian and New Zealand Clinical Trial Registry (Trial ID: ACTRN12621000760875).

149

150 Study objectives

The primary objective was to evaluate the safety and tolerance of NTI-164 in children 151 with ASD throughout the trial. In addition to assessment questionnaires, safety data were 152 collected through laboratory tests, including full blood examination, liver and renal function 153 tests performed at screening and at the beginning of week five during hospital visits. The 154 secondary objective was to assess the efficacy of NTI-164 in treating ASD-associated 155 symptoms. Efficacy data were collected through physician, parent (or caregiver) and school-156 aged participant-reported questionnaires at two designated time points. This study explored the 157 effect of NTI-164 on core behavioural symptoms of children with ASD and associated 158 symptoms, including irritability, hyperactivity, mood, anxiety, sleep disorders and self-159 stimulation. 160

161

162 **Pharmacological Intervention**

163 The chemical composition profile of the investigational product NTI-164 consisted of 164 62% Cannabidiolic Acid (CBDA), 14% Cannabidiol (CBD), 0.44% Cannabigerolic Acid 165 (CBGA), 0.06% Cannabidivarin (CBDV) and 0.08% Tetrahydrocannabinol (THC). The

investigational product was provided and dispensed in a glass jar as a 53 mg/mL oil-based solution ready for self-administration at home. During the initial hospital visit (baseline), the participants received the packaged investigational product with instructions. Participants were also given access to a web app (Caspio Participant Portal) to record daily drug administration.

Several lines of evidence from controlled trials have shown the effectiveness of CBD 170 at a dose of 20 mg/kg in managing seizures [62-64]. Therefore, this dose was used in the current 171 study, with participants starting treatment on a daily dose of 5mg/kg of NTI-164 at baseline. 172 To minimise the risk of undesired side effects, the dose was increased by 5mg/kg weekly to 173 reach the maximum tolerated daily dose or 20 mg/kg daily. The daily dose was calculated by 174 multiplying the dosage by each patient's weight and then dividing by the concentration of 175 CBDA in the oil (53mg/mL). This provided a total daily volume in mL divided into twice daily 176 doses. Protocol adherence was assessed by the accountability of returned investigational 177 product and packaging at the end of the four weeks. 178

179

180 Outcome measures

181 **Primary outcome measure**

The primary endpoint was safety and tolerability of NTI-164 treatment as determined by monitoring and assessment through standard laboratory tests of full blood examination, liver and renal function tests, as well as vital signs in addition to physician and parent (or caregiver) reported questionnaires completed at baseline and after completion of 4 weeks of treatment.

Adverse events were assessed and evaluated by designated study staff through discussions with the participant at the scheduled study visit after the end of four weeks, as well as through phone contacts and clinically significant laboratory results. Whenever an adverse

event was reported during treatment at home, the Principal Investigator was notified immediately via the online portal. The Principal Investigator or a designated study staff member promptly followed all adverse events. Documentation of adverse events included details of the event, dates and times, severity, duration and possible relationship to the investigational product.

194 Secondary outcome measure

The efficacy assessments included the administration of both quantitative and qualitative ASD-related questionnaires, with the first four scales described below completed by both the caregiver and clinician. The selected questionnaires were specific to various comorbidities associated with autism spectrum disorder. The purpose was to evaluate the impact of NTI-164 on symptoms associated with autism spectrum disorder. All scales were administered at baseline (week 1) and post-baseline (week 5).

201 1. Clinical Global Impression of Improvement for the Caregiver (CGI-I-Ca) [65]: This is a 7202 point scale measuring symptom change from baseline.

203 2. Clinical Global Impression of Improvement for the Clinician (CGI-I-C) [65]: This is a 7204 point scale measuring symptom change from baseline.

3. Caregiver Global Impression of Change (CGI-C) Target Behaviour [65]: Reflects clinician's
impression of behaviour change on a 7-point scale ranging from 1=not at all to 7=very severe
problem.

4. Clinical Global Impression of Change in Attention (CGI-CA) [65]: Reflects clinician's
impression of change in attention on a 7-point scale ranging from 1=not at all to 7=very severe
problem.

5. Clinical Global Impression of Severity of Illness (CGI-S) [65]: Reflects clinician's
impression of severity of illness on a 7-point scale ranging from 1=not at all to 7=among the
most extremely ill.

6. Anxiety Scale for Children - autism spectrum disorder – Parent Version (ASC-ASD-P) [66]:

- Parent/Caregiver form was developed to detect anxiety symptoms in youth with ASD. They
 are composed of four subscales: Performance Anxiety, Uncertainty, Anxious Arousal, and
 Separation Anxiety. Items are rated on a 4-point scale (0=never and 3=always). Subscales sum
 to equal a total score.
- 219 7. Anxiety Scale for Children autism spectrum disorder Child Version (ASC-ASD-C) [66]::

Child form developed to detect symptoms of anxiety in youth with ASD. Composed of the four
Subscales: Performance Anxiety, Uncertainty, Anxious Arousal, and Separation Anxiety.
Items are rated on a 4-point scale (0=never and 3=always). Subscales sum to equal a total
anxiety score, with lower scores indicating a decreased level of anxiousness. The total score
ranged from 6 to 55 and 3 to 50 out of a possible maximum score of 72 for the ASC-ASD-P
and ASC-ASD-C version, respectively.

8. Sleep Disturbance Scale for Children (SDSC) [67]: Includes the six subscales of Disorders
of Initiating and Maintaining Sleep, Sleep Breathing Disorders, Disorders of Arousal, Sleep
Wake Transition Disorders, Disorders of Excessive Somnolence, and Sleep Hyperhydrosis.
Items are rated on a 5-point scale where 1=never and 5=always (daily). Subscale scores sum to
equal a total sleep score, with a higher score reflecting more sleep-related problems.

231

232 Study procedures

The study schedule of procedures and assessments is presented in Table 1. Participants 233 were recruited through Monash Children's Hospital (MCH) in Melbourne, Australia, Potential 234 participants attended a screening visit for assessment based on study selection criteria (See 235 Supplementary information, File 1) and were provided with the Participant Information Sheet 236 and Consent Form. After obtaining written informed consent from caregivers, eligible 237 participants underwent a physical assessment, including vital signs, anthropometric 238 measurements, full blood examination, liver and renal function tests as part of the screening 239 process. In case of restrained compliance with blood sample collection, analgesia with nitrous 240 241 oxide was administered by a trained staff member. At this visit, a parent survey was obtained concerning the medical and family history of the participating child, including current 242 attendance at specific programs or health service utilisation. 243

Table 1. Study schedule of procedures and assessments for the 28 day open-label trial.

Assessments	Screeni	Visit 1/	Visit 2 /
Assessments	ng	Week 1	Week 5
Day	-14 to -1	1	29
CGI-I-Ca Baseline		Х	
CGI-I-Ca Post-baseline			Х
CGI-I-C Baseline		Х	
CGI-I-C Post-baseline			Х
CGI-C Baseline		Х	
CGI-C Post-baseline			Х
CGI-CA Baseline		Х	
CGI-CA Post-baseline			Х
CGI-S		Х	Х

Assessments	Screeni	Visit 1/	Visit 2 /	
Assessments	ng	Week 1	Week 5	
SDSC		Х	Х	
ASC-ASD-P		Х	X	
ASC-ASD-C		Х	X	
Parent survey	X			
Medical history	X			
Concomitant medications	X	Х	Х	
Physical examination (including vital signs)	X	X	X	
Weight measurement	X	X	X	
Height measurement	X			
FBE	X		Х	
LFT	X		Х	
UEC	X		Х	
Dispense study medication		Х	X	
Collection returned IP			Х	
Drug administration		Xda	uilyX	
Caspio Participant Portal (web app)		XX		
Caspio Physician Portal (web app)	X	X	Х	
Evaluation measures		X	Х	
Safety outcome measure		Х	Х	

Assessments	Screeni ng	Visit 1/ Week 1	Visit 2 / Week 5
Adverse events		Х	Х
Accountability		Х	Х

Abbreviations ASC-ASD-C: Anxiety Scale for Children - Autism Spectrum Disorder; ASC-ASD-P: Anxiety
Scale for Children - Autism Spectrum Disorder - Parent Versions; CGI-I-Ca: Clinical Global Impression of
Improvement for the Caregiver; CGI-I-C: Clinical Global Impression of Improvement for the Clinician; CGI-C:
Caregiver Global Impression of Change; CGI-CA: Caregiver Global Impression of Change in Attention; CG-S:
Clinical Global Impression–Severity; SDSC: Sleep Disturbance Scale for Children.

At the first visit in week 1 (baseline), participants completed all the required 250 questionnaires and the first daily dose of 5mg/kg of the investigational product NTI-164 was 251 administered. The participant was monitored for 2 hours for any immediate adverse events. 252 Participants who did not report any adverse events were dispensed with NTI-164 for four weeks 253 and instructed to administer the daily volume orally over two doses. Instructions were provided 254 255 on administering increasing the dose of the product to a maximum of 20mg/kg/day from home. Participants were also trained to use the study web app (Caspio Participant Portal) to record 256 drug administrations, report adverse events, and complete questionnaires from home. 257

Once the four-week treatment was completed, at the start of the week 5 visit (postbaseline), participants underwent the same set of laboratory tests and physical assessments as before and completed all specified post-baseline questionnaires. To ensure adherence to study protocol and accountability, returned product and packaging were collected and recorded at this visit.

263

264 Statistical analysis

The safety and tolerability were assessed by recording the frequency and severity of 265 reported adverse events by all treated participants. The distribution was analysed using patient 266 demographics, laboratory values and vital signs. Given the small sample size of this study, 267 descriptive statistical analyses of the mean score, mean change, and Standard Deviation (SD) 268 were performed on quantifiable outcome measures. The Wilcoxon Signed-Rank Test and the 269 Paired t-test were used to assess the statistical significance of the analysed data sets. The final 270 statistical analysis included all participants completing the initial four week treatment phase. 271 The CGI-S scale was used to analyse the therapeutic effect of NTI-164 and its changes to the 272 severity of illness. The ASC-ASD-C and ASC-ASD-P questionnaires were used to assess 273 anxiety across four sub-domains, and the SDSC was used to assess changes to sleep from 274 baseline and at the end of the 4 weeks. Clinical Global Impression scales were used to analyse 275 276 efficacy by measuring symptom change from baseline. Each CGI survey uses the same 7-point scale to measure symptom change from baseline: Very much improved, Much improved, 277 Minimally improved, No change, Minimally worse, Much worse and Very much worse. 278

279

280 **Results**

281

282 **Participant characteristics**

Fourteen of the 18 participants enrolled in the study completed the full treatment. One patient withdrew before treatment began, and three patients discontinued during treatment. Most of the treated patients were male (9/14), Caucasian (12/14), and had an average age of 13.4 years (ranging from 10-17 years). All active patients were diagnosed with ASD Level 2/3 and were evaluated at baseline as "Mildly ill" (4 patients), "Moderately ill" (4 patients),

"Markedly ill" (3 patients), or "Severely ill" (3 patients), according to the CGI-Severity of
Illness scale. The average daily dose for treated patients was 16.7 mg/kg/day. About 64% of
patients could tolerate the maximum dose of 20 mg/kg/day, while 36% tolerated a maximum
daily dose ranging between 6 mg/kg/day and 19 mg/kg/day.

292

293 Safety and tolerability

Eight participants experienced ten mild to moderate adverse events, totalling 17 adverse 294 reports during treatment. One participant discontinued treatment. The most frequent side-effect 295 was gastrointestinal symptoms reported by a third of participants (36%). None of these side 296 297 effects were severe enough to significantly interfere with the patient's functioning. Most 298 patients were advised to rest to treat these transient adverse effects (Table 2). No serious adverse events or deaths related to the investigational drug were reported during the study. The 299 300 safety data indicated that NTI-164 at 5, 10, 15 and 20 mg/kg administered in two daily doses is safe and well-tolerated in this study population. Laboratory values provide further safety 301 support. No changes were observed in patients' full blood examination, liver function or kidney 302 function tests (Table 3). Also, no changes were observed to the vital signs of active patients 303 during treatment, further corroborating that NTI-164 was well-tolerated. 304

Table 2. Reported adverse events during the trial.*

Adverse Event	Total No. of	Frequency	Treatment
	Reports	(%)	
Abdominal pain	3	14%	Rest
Lack/loss of appetite	3	14%	None
Diarrhoea	2	9%	None
Vomiting	2	9%	None

Lethargy	2	9%	Rest
Hypoglycaemia	1	5%	None
Rashes**	1	5%	Zyrtec for
			itchiness
Itchiness without	1	5%	Warm shower
rash			
Sore Throat	1	5%	Rest
Upper Respiratory	1	5%	Treated by
Tract Infection			doctor

- 306 * Two participants were excluded as one had ingrown nail infection and one had knee
- 307 surgery
- 308 ** This participant discontinued during the treatment and did not complete the study
- 309
- **Table 3.** Evaluation of clinical laboratory parameters (n=12) at timepoint 1 (screening visit)
- and timepoint 2 (start of week 5).

Parameter		Timepoint	1	Timepoint 2			Median
	Mean	Minimu	Maxim	Mean	Minimu	Maximu	Change
		m	um		m	m	
Sodium	139	136	142	139	137	141	-1
Potassium	4.3	3.8	4.8	4.4	3.7	4.8	0
Chloride	104	102	108	104	101	106	1
Bicarbonat	25	19	29	25	22	30	0
e							
Urea	4.6	3.1	6.1	4.1	2.6	5.9	0.2

Creatinine	47	35	68	50	36	73	3
Glucose	4.9	3.3	6.3	4.5	2	7.1	-0.1
ALP	287	101	438	280	82	424	-23
GGT	17	11	25	15	8	29	-0.5
ALT	24	5	57	26	6	48	0
Total	11	4	40	9	4	14	0
Bilirubin							
Haemoglob	133	115	147	133	119	144	2
in							
RBC	4.69	4.1	5.34	4.74	4.36	5.11	0.11
MCV	83	75	90	84	77	90	1.5
МСН	32.4	25.2	86	28.2	25.5	30.8	0.3
МСНС	342	331	349	337	330	348	2
RDW	13.5	12.4	16.7	13.7	12.6	16.9	0.3
WCC	7.6	4.8	14.6	7.0	4.4	11.4	-1
Neutrophil	3.94	1.7	8.69	3.47	1.79	4.7	-0.66
S							
Lymphocyt	2.66	1.45	6.16	2.54	1.15	4.73	-0.035
es							
Monocytes	0.54	0.31	0.79	0.55	0.35	1.05	-0.06
Eosinophil	0.45	0.1	1.24	0.41	0.03	1.14	-0.05
S							
Basophils	0.05	0	0.09	0.06	0	0.1	0.02
Platelets	294	190	413	301	214	422	-13.5

- **Abbreviations**. ALP : Alkaline Phosphatase; ALT : Alanine Transaminase; GGT: Gamma-
- 314 Glutamyl Transferase; MCH: Mean Corpuscular Haemoglobin; MCHC: Mean Corpuscular
- Haemoglobin Concentration; MCV: Mean Corpuscular Volume; RBC: Red blood cell;
- RDW: Red Cell Distribution Width; WCC: White Cell Count.
- 317

318 Analysis of therapeutic efficacy

319 Clinical Global Impression-Severity (CGI-S)

The Clinical Global Impression-Severity (CGI-S) scale was used to assess global improvement, the severity of illness, and the efficacy index based on drug effect only (Table 4). Of the 14 treated patients, 13 (93%) showed symptomatic improvement. 64% of these patients showed a global improvement of 'Much improved', 29% showed 'Minimally improved', and only one patient (7%) had 'No change' (Figure 1).

325 Fig 1. Clinical Global Impression – Global Improvement.

Table 4. Symptom change scores for each Clinical Global Impression (CGI) scale.

CGI Assessment	Symptom Change from Baseline					
	1. Very 2. Much 3.		3.	4. No		
	much	improved	Minimally	change		
	improved		improved			
CGI of Severity of Illness	0	9 (64%)	4 (29%)	1 (7%)		
(CGI-S)						
CGI of Improvement for the	1 (7%)	7 (50%)	4 (29%)	2 (14%)		
Caregiver						

(CGI-I-Ca)				
CGI of Improvement for the	1 (7%)	4 (29%)	7 (50%)	2 (14%)
Clinician				
(CGI-I-C)				
CGI of Change in Target	2 (14%)	4 (29%)	3 (21%)	5 (36%)
Behaviour				
(CGI-C)				
CGI of Change in Attention	0	3 (21%)	4 (29%)	7 (50%)
(CGI-CA)				

327

At baseline, the average rating for the severity of illness was 4.4, which was reduced to an average rating of 3.6 after 28 days of NTI-164 treatment (Figure 2). The mean difference of CGI-S between 28 days of treatment and baseline was -0.714 (95% CI: -1.332, -0.097, p=0.027), with the Wilcoxon Signed-Rank Test statistic showing a significant difference of -15 (p=0.047).

Fig 2. Clinical Global Impression – Severity of Illness.

At the end of the study, 14% of active patients receiving daily treatment with NTI-164 334 demonstrated the second highest possible efficacy index of 2, indicating marked therapeutic 335 effects with side effects that did not significantly interfere with functioning. Clinicians rated 336 337 NTI-164 to have a moderate therapeutic effect (efficacy index of 5 or 6) in 72% of treated patients, with half having no side effects and the other half having side effects that did not 338 significantly interfere with functioning. A minimal therapeutic effect (efficacy index of 9) was 339 observed in 7%, and an unchanged therapeutic effect (efficacy index of 13) in just one 340 341 participant (Figure 3).

342 Fig 3. Clinical Global Impression - Therapeutic Effect after 28 days of treatment.

343

344 Anxiety symptoms

To measure anxiety symptoms in treated participants with ASD, the Anxiety Scale for 345 346 Children, both -Parent and -Child versions (ASC-ASD) were used. The mean scores, Wilcoxon Signed-Rank test, and corresponding *p* values for both ASC-ASD-P and ASC-ASD-C versions 347 are summarised and reported in Table 5. The total score of the Anxiety Scale for Children was 348 reduced in more than half of both parents (62%) and children (54%) scales after four weeks of 349 treatment. During the same period, nearly a quarter of parents (23%) and a third of children 350 (36%) reported increased levels of anxiousness, while 15% and 9% of parents and children 351 reported no change, respectively. The mean change for the total score of the ASC-ASD parent 352 version was significantly reduced by 14% (*p*=0.0414), while the child version of the scale was 353 non-significantly reduced by 6.8% after four weeks of treatment. The most frequently endorsed 354 items on the ASC-ASD-P and ASC-ASD-C were from the Uncertainty (mean change 15.6%) 355 and Separation Anxiety (25.4%) subscales post-treatment, respectively (Table 5). 356

|--|

Assessment	Baseline	Week 5	Mean	Wilcoxon signed
			change	rank test
				(P value)
Anxiety Scale for Childre	n – Parent Vers	ion (ASD-ASC-I	P) n=11	
Total ASC-ASD	31.5± 14.7	27.1±12.9	-4.4	47.5 (0.0414)
Performance Anxiety	7.5±4.4	6.5±3.7	-1.0	25.5 (0.0474)
Anxiety Arousal	4.0± 3.9	3.9±3.2	-0.1	15.0 (0.865)

Separation Anxiety	5.3±4.1	4.9±4.0	-0.4	17.5 (0.139)
Uncertainty	14.1± 5.8	11.9± 4.4	-2.2	47.0 (0.0459)
Anxiety Scale for Childre	en – Child Versio	on (ASD-ASC-C)	n=9	
Total ASC-ASD	30.9±10.1	28.8±13.3	-2.1	33.0 (0.213)
Performance Anxiety	6.6± 3.9	6.1± 3.3	-0.5	21.0 (0.206)
Anxiety Arousal	4.3± 3.7	5.4± 3.1	1.1	11.5 (0.360)
Separation Anxiety	6.7± 3.6	5.0± 4.4	-1.7	37.0 (0.0834)
Uncertainty	13.3± 4.9	12.2± 5.5	-1.1	26.0 (0.258)

358

359 Sleep quality and sleep disturbances

To assess changes to sleep quality, the SDSC questionnaire was used. Of the 14 study participants, 11 children completed sleep assessment before and after 28 days of treatment. Although the total sleep score decreased from baseline to post-treatment, it was not statistically significant. The scores for all sleep outcomes except Disorders of excessive somnolence improved non-significantly from baseline to post-treatment (Table 6).

365	Table 6 Sleep Disturbances	Scale for Children	(SDSC). Res	sults are expressed as Mean \pm SD
	1			1

Sleep Domains	Baseline	Week 5	Mean	Wilcoxon
			difference	signed-rank
				test
				(p value)
Total Score (n=11)	50.5±17.1	48.4±13.4	-2.0	29 (0.721)
Disorder of initiating &	17.6± 6.9	16.4 ± 6.3	-1.2	24.5 (0.811)
maintaining sleep				

Sleep breathing disorders	6.0 ± 3.0	5.5±2.3	-0.5	16 (0.234)
Disorders of arousal	4.0±1.6	3.9±1.2	-0.1	3 (1)
Sleep-wake transition	11.9± 4.4	11.2± 3.3	-0.7	15 (0.343)
disorders				
Disorders of excessive	8.3±3.3	9.1±3.7	0.8	13 (0.481)
somnolence				
Sleep hyperhydrosis	2.7±1.2	2.4± 0.9	-0.3	5 (0.285)

366

367

368 **Discussion**

The current pharmacological and behavioural interventions are limited in treating a 369 considerable portion of children with ASD-related symptoms due to a lack of efficacy or 370 adverse side effects that interfere with daily functioning. Therefore, there is an urgent need for 371 a more concerted effort in clinical research to develop effective and safer therapies for 372 addressing ASD associated comorbid symptoms. While the available evidence from controlled 373 studies on the role of medicinal *Cannabis sativa* in the management of children with ASD is 374 limited, a large body of evidence from preclinical studies has demonstrated the positive effects 375 of cannabinoids in the modulation of a wide range of biological responses in particular 376 neurodevelopmental processes. Furthermore, emerging evidence from recent observational 377 studies [53-55, 57] has indicated that a synergistic and entourage pharmacological effect of 378 Cannabis sativa derivatives can contribute to improved ASD-related symptoms and 379 comorbidities in children. Therefore, this study sought evidence for the safety and efficacy of 380 NTI-164, a full spectrum botanical product, per the entourage effect in managing ASD 381 comorbid symptoms in paediatric patients. The findings demonstrate that NTI-164 is safe and 382

well-tolerated in children up to 20 mg/kg daily dose with transient side effects that did not
significantly interfere with the general functioning of treated patients.

Furthermore, NTI-164 exhibited statistically significant efficacy in improving ASD 385 core and associated symptoms after four weeks of treatment. In particular, following NTI-164 386 treatment, targeted behavioural problems were much improved or very much improved in 387 nearly half of the patients. More than half of caregivers and children also reported consistent 388 improvements in the anxiety level of participants. Despite the limited sample size with 389 completed sleep data, the overall direction of change indicated improved sleep outcomes and 390 warrants further longitudinal evaluation. Based on these promising findings, we have initiated 391 an extended treatment open-label trial for 57 weeks to assess long-term NTI-164 safety and 392 efficacy in children and adolescents with ASD and related comorbidities. 393

394

Impact of full-spectrum cannabis extract on ASD core symptoms

The safety profile and tolerability of NTI-164 were favourable in the patients who 396 completed treatment consistent with previous clinical studies that used whole plant medicinal 397 cannabis extract to treat children and adolescents with ASD-related symptoms [52-58]. The 398 399 most frequent side-effect in our cohort was related to gastrointestinal symptoms, which were transient and improved with rest by the end of the treatment phase. However, the majority of 400 clinical studies using full-spectrum cannabis extract for the treatment of children with ASD 401 402 reported mild or transient adverse events frequently related to sleep disturbances [52-55, 58, 59], anxiety or irritability symptoms [52, 55, 57, 58] which were absent in our cohort. This 403 might be due to different strains with variable composition of phytocannabinoids and higher 404 doses of THC than our full-spectrum medical cannabis extract with negligible THC (0.08%). 405 Alternatively, side-effects not observed in our study might be due to other studies, including 406

primarily children diagnosed with severe ASD, since sleep disturbances have been reported as 407 a side-effect of isolated CBD treatment in children with severe behavioural problems [68]. In 408 addition, several studies have found that the severity of ASD core symptoms is associated with 409 the severity of sleep disturbances in younger children [60, 69, 70]. Compared to other clinical 410 studies that included children as young as four years old, our active patients were much older 411 (10-17 years). The effect of different compositions of phytocannabinoids and THC levels in 412 full-spectrum extracts on the severity of ASD symptoms in younger children, therefore, 413 requires further investigation. 414

This is the first study of full-spectrum cannabis extract treatment in children with ASD 415 to report subjective measures of adverse events and objective measures of biochemical analysis 416 and vital signs following treatment. In a prospective cohort study of biochemical safety analysis 417 of an oil-based full-spectrum cannabis product, all parameters were within the normal range in 418 children with ASD after three months of treatment [71]. However, this study did not report an 419 evaluation of adverse events or vital signs following treatment. Notably, a recent randomised 420 controlled feasibility study reported no significant abnormal biochemical test results after eight 421 weeks of therapy with isolated CBD in children with severe behavioural problems and 422 intellectual disability [68]. 423

In our study, overall daily treatment with NTI-164 for four weeks significantly 424 improved symptoms in 93% of active patients, with nearly two-thirds of children rated by 425 clinicians to exhibit moderate effects following treatment. Similarly, several cohort studies in 426 children using full-spectrum products have demonstrated significant overall improvement in 427 ASD symptoms reported by parents [52-54, 56] and clinicians [55, 57]. Specifically, we found 428 that almost half of treated children with ASD showed reduced disruptive behaviour consistent 429 with other studies that have demonstrated improvement in behavioural problems ranging from 430 32% to 90%, including adaptive behaviours, self-injury and hyperactivity [53, 57, 59]. Social 431

interaction and communication have also significantly improved following treatment with full-432 spectrum cannabis extract in children with ASD-related symptoms [52, 55-57]. In addition, 433 two randomised controlled trials have shown that cannabinoid treatment, compared to placebo 434 in children, was safe with acceptable tolerability and effective at reducing ASD-associated 435 disruptive behaviours [58, 59]. However, compared to pure cannabinoids, there was no 436 apparent difference with improvements observed for treatment with whole-plant extract after 437 12 weeks. The clinical benefits of the entourage effects of our cannabis strain compared to 438 purified cannabinoids remain to be further explored in longitudinal controlled studies. 439

440

441 Impact of full-spectrum cannabis extract on ASD-related comorbidities

In addition to improvements in behavioural outcomes, a recent systematic review of the 442 evidence for medicinal cannabis in ASD treatment found benefits for a broad range of 443 comorbidities, including cognition, anxiety and sleep disturbances in adults and children [72]. 444 Consistent with previous studies [52-54], we also found that after four weeks of treatment with 445 full-spectrum cannabis extract, anxiety symptoms were reduced in more than half of our cohort 446 based on both parent and children reported anxiety questionnaires. In particular, the parent-447 rated total scores and the performance anxiety and uncertainty subscales significantly improved 448 for children with ASD. However, the magnitude of improvement on child-rated outcome 449 measures did not reach statistical significance despite the direction of change, suggesting 450 reduced anxiety symptoms in half of the treated patients. This rating discrepancy might be due 451 to differences in perceptions of anxiety for children with ASD and their parents with the 452 severity of ASD symptoms reportedly contribute to the disparity in parent-child anxiety rating 453 where higher severity levels were shown to be associated with the tendency for parent ratings 454 to exceed child anxiety rating [73]. Nevertheless, this finding highlights the clinical implication 455

of self-report rating to inform areas of concern for continued assessment of anxiety symptomsin children with ASD.

While previous prospective cohort studies have reported treatment with whole plant 458 cannabis extract of various strains significantly improved sleep outcomes in children with ASD 459 [53-55], a recent randomised controlled trial did not find any difference between cannabinoid 460 treatment and placebo in sleep parameters after 12 weeks [60]. We also did not find significant 461 improvement in any of the sleep domains as measured by a validated sleep questionnaire. These 462 inconsistencies could be due to differences in treated participant characteristics, especially 463 level of ASD severity, age, instruments used to measure sleep or strain of cannabis with various 464 phytocannabinoid composition. In addition, since the previous studies that reported improved 465 sleep outcomes were over several months, this may indicate the need for a longer period before 466 any benefit in sleep quality can be observed from treatment with cannabinoid extract. 467

These findings support the safety and efficacy of full-spectrum products and promisingentourage effects of cannabinoids in treating children with ASD-related symptoms.

470

471 **Limitations**

There were several limitations in this study. Since our study was an open-label design to collect preliminary data on the safety and efficacy of NTI-164 treatment of symptoms in children with ASD, no control group was included. However, the addition of objective measures of vital signs and biochemical analysis to subjective reports of adverse events further strengthened the NTI-164 safety profile in treated children with ASD. Nevertheless, further research for long-term evaluation of safety data of NTI-164 botanical product for the treatment

of children with ASD symptoms, especially in terms of interaction with concomitantmedications, is needed.

Given that the sample size was small, evaluation of the impact of NTI-164 treatment on subgroups of children with various ASD severity was not possible. Although data was collected on concomitant medications prescribed for ASD-related comorbidities, this study was not powered to determine the impact of chronic medication on treatment response. Also, we only used subjective measures of sleep outcomes, and future studies should include actigraphy or polysomnography together with sleep diaries as objective measurements of sleep quality.

486

487

488 Conclusions

This open-label study provided preliminary efficacy and safety data on a novel botanical 489 formulation of phytocannabinoids in treating symptoms in children with ASD and associated 490 comorbidities. Results indicate that NTI-164 is safe and well-tolerated, with significant 491 efficacy in improving disruptive behaviours and reducing anxiety in this Pediatric cohort. The 492 findings of this study further contribute to the accumulating evidence in favour of whole plant 493 cannabis extracts, with most participants reporting a clinically meaningful change in ASD-494 related symptoms and associated anxiety. Despite the small sample size, objective safety 495 analysis together with converged evidence from standardised clinician, parent and child-496 reported questionnaires with respect to overall improvement strengthen the evidence for the 497 benefit of full-spectrum cannabis extract in the treatment of children with ASD-related 498 symptoms. Furthermore, these results are consistent with other prospective cohort studies of 499

- 500 full-spectrum cannabis extract and support further evaluation of the clinical benefits of whole
- 501 plant extracts in rigorous placebo-controlled trials of longer duration in this patient population.
- 502

503

504 **References**

- American Psychiatric Association. Diagnostic and statistical manual of mental
 disorders: American Psychiatric Publishing; 2013.
- 2. Lord C, Brugha TS, Charman T, Cusack J, Dumas G, Frazier T, et al. Autism

spectrum disorder. Nat Rev Dis Primers. 2020;6(1):1-23.

3. Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric

510 disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated

511 factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry.

- **512** 2008;47(8):921-9.
- Evers K, Maljaars J, Schepens H, Vanaken GJ, Noens I. Conceptualization of quality
 of life in autistic individuals. Dev Med Child Neurol. 2022;64(8):950-6.
- 515 5. Van Heijst BF, Geurts HM. Quality of life in autism across the lifespan: A meta516 analysis. Autism. 2015;19(2):158-67.
- 517 6. Salari N, Rasoulpoor S, Rasoulpoor S, Shohaimi S, Jafarpour S, Abdoli N, et al. The
 518 global prevalence of autism spectrum disorder: a comprehensive systematic review and meta519 analysis. Ital J Pediatr 2022;48(1):1-16.

520	7.	Kang L, Liu J, Liu Y, Liang W, Yang F, Liu M. Global, regional, and national disease
521	burder	n of autism spectrum disorder among children under 5 years from 1990 to 2019: An
522	analys	is for the Global Burden of Disease 2019 Study. Asian Journal of Psychiatry.
523	2023;7	79:103359. doi: https://doi.org/10.1016/j.ajp.2022.103359.
524	8.	Bieleninik Ł, Gold C. Estimating components and costs of standard care for children
525	with a	utism spectrum disorder in Europe from a large international sample. Brain Sci.
526	2021;1	11(3):340.
527	9.	Cakir J, Frye RE, Walker SJ. The lifetime social cost of autism: 1990–2029. Res
528	Autisr	n Spectr Disord. 2020;72:101502. doi: 10.1016/j.rasd.2019.101502.
529	10.	Blaxill M, Rogers T, Nevison C. Autism Tsunami: the Impact of Rising Prevalence on
530	the So	cietal Cost of Autism in the United States. J Autism Dev Disord. 2022;52(6):2627-43.
531	doi: 10	0.1007/s10803-021-05120-7.
532	11.	Aishworiya R, Valica T, Hagerman R, Restrepo B. An Update on
533	Psych	opharmacological Treatment of Autism Spectrum Disorder. Neurotherapeutics.
534	2022;1	19(1):248-62. doi: 10.1007/s13311-022-01183-1.
535	12.	Anagnostou E. Clinical trials in autism spectrum disorder: evidence, challenges and
536	future	directions. Curr Opin Neurol. 2018;31(2):119-25.
537	13.	Persico AM, Ricciardello A, Lamberti M, Turriziani L, Cucinotta F, Brogna C, et al.
538	The pe	ediatric psychopharmacology of autism spectrum disorder: A systematic review - Part I:
539	The pa	ast and the present. Prog Neuropsychopharmacol Biol Psychiatry. 2021;110:110326.
540	doi: <u>ht</u>	tps://doi.org/10.1016/j.pnpbp.2021.110326.

Edgcomb JB, Zima B. Medication Adherence Among Children and Adolescents with
Severe Mental Illness: A Systematic Review and Meta-Analysis. J Child Adolesc
Psychopharmacol. 2018;28(8):508-20. Epub 2018/07/25. doi: 10.1089/cap.2018.0040. PMID:

544 30040434.

545 15. Cheroni C, Caporale N, Testa G. Autism spectrum disorder at the crossroad between

546 genes and environment: contributions, convergences, and interactions in ASD developmental

547 pathophysiology. Mol Autism. 2020;11(1):69. doi: 10.1186/s13229-020-00370-1.

548 16. Jeste SS, Geschwind DH. Disentangling the heterogeneity of autism spectrum

disorder through genetic findings. Nat Rev Neurol. 2014;10(2):74-81. Epub 2014/01/29. doi:

550 10.1038/nrneurol.2013.278. PMID: 24468882.

551 17. Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid
552 system in neurological disorders. Nat Rev Neurol. 2020;16(1):9-29. Epub 2019/12/14. doi:

553 10.1038/s41582-019-0284-z. PMID: 31831863.

Melis M, Greco B, Tonini R. Interplay between synaptic endocannabinoid signaling
and metaplasticity in neuronal circuit function and dysfunction. Eur J Neurosci.
2014;39(7):1189-201. Epub 2014/04/10. doi: 10.1111/ejn.12501. PMID: 24712998.

557 19. Wei D, Lee D, Cox CD, Karsten CA, Peñagarikano O, Geschwind DH, et al.

558 Endocannabinoid signaling mediates oxytocin-driven social reward. Proc Natl Acad Sci U S

A. 2015;112(45):14084-9. Epub 2015/10/28. doi: 10.1073/pnas.1509795112. PMID:

560 26504214.

20. Chakrabarti B, Persico A, Battista N, Maccarrone M. Endocannabinoid Signaling in
Autism. Neurotherapeutics. 2015;12(4):837-47. Epub 2015/07/29. doi: 10.1007/s13311-0150371-9. PMID: 26216231.

- 564 21. Marco EM, Laviola G. The endocannabinoid system in the regulation of emotions
- throughout lifespan: a discussion on therapeutic perspectives. J Psychopharmacol.
- 566 2012;26(1):150-63. Epub 2011/06/23. doi: 10.1177/0269881111408459. PMID: 21693551.
- 567 22. Zou M, Li D, Li L, Wu L, Sun C. Role of the endocannabinoid system in neurological
- disorders. Int J Dev Neurosci. 2019;76:95-102. Epub 2019/03/13. doi:
- 569 10.1016/j.ijdevneu.2019.03.002. PMID: 30858029.
- 570 23. Pietropaolo S, Marsicano G. The role of the endocannabinoid system as a therapeutic
- target for autism spectrum disorder: Lessons from behavioral studies on mouse models.
- 572 Neurosci Biobehav Rev. 2022;132:664-78. Epub 2021/11/24. doi:
- 573 10.1016/j.neubiorev.2021.11.031. PMID: 34813825.
- 574 24. Zamberletti E, Gabaglio M, Woolley-Roberts M, Bingham S, Rubino T, Parolaro D.
- 575 Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal
- 576 Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure
- 577 in Rats. Front Cell Neurosci. 2019;13:367. Epub 2019/08/27. doi: 10.3389/fncel.2019.00367.
- 578 PMID: 31447649.
- 579 25. Kerr DM, Downey L, Conboy M, Finn DP, Roche M. Alterations in the
- endocannabinoid system in the rat valproic acid model of autism. Behav Brain Res.
- 581 2013;249:124-32. Epub 2013/05/07. doi: 10.1016/j.bbr.2013.04.043. PMID: 23643692.
- Aran A, Eylon M, Harel M, Polianski L, Nemirovski A, Tepper S, et al. Lower
 circulating endocannabinoid levels in children with autism spectrum disorder. Mol Autism.
 2019;10(1):2. doi: 10.1186/s13229-019-0256-6.

585	27. Karhson DS, Krasinska KM, Dallaire JA, Libove RA, Phillips JM, Chien AS, et al.
586	Plasma anandamide concentrations are lower in children with autism spectrum disorder. Mol
587	Autism. 2018;9:18. Epub 2018/03/23. doi: 10.1186/s13229-018-0203-y. PMID: 29564080.
588	28. Siniscalco D, Sapone A, Giordano C, Cirillo A, de Magistris L, Rossi F, et al.
589	Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear
590	cells of children affected by autistic disorders. J Autism Dev Disord. 2013;43(11):2686-95.
591	Epub 2013/04/16. doi: 10.1007/s10803-013-1824-9. PMID: 23585028.
592	29. Schiavi S, Manduca A, Carbone E, Buzzelli V, Rava A, Feo A, et al. Anandamide and
593	2-arachidonoylglycerol differentially modulate autistic-like traits in a genetic model of autism
594	based on FMR1 deletion in rats. Neuropsychopharmacology. 2022. Epub 2022/09/17. doi:
595	10.1038/s41386-022-01454-7. PMID: 36114286.
596	30. Wei D, Dinh D, Lee D, Li D, Anguren A, Moreno-Sanz G, et al. Enhancement of
597	Anandamide-Mediated Endocannabinoid Signaling Corrects Autism-Related Social
598	Impairment. Cannabis Cannabinoid Res. 2016;1(1):81-9. Epub 2016/02/01. doi:
599	10.1089/can.2015.0008. PMID: 28861483.
600	31. Qin M, Zeidler Z, Moulton K, Krych L, Xia Z, Smith CB. Endocannabinoid-mediated
601	improvement on a test of aversive memory in a mouse model of fragile X syndrome. Behav
602	Brain Res. 2015;291:164-71. Epub 2015/05/17. doi: 10.1016/j.bbr.2015.05.003. PMID:
603	25979787.
604	32. Arnold JC, McCartney D, Suraev A, McGregor IS. The safety and efficacy of low

oral doses of cannabidiol: An evaluation of the evidence. Clinical and translational science.
2023;16(1):10-30.

607 33. Chesney E, Oliver D, Green A, Sovi S, Wilson J, Englund A, et al. Adverse effects of
608 cannabidiol: a systematic review and meta-analysis of randomized clinical trials.
609 Neuropsychopharmacology. 2020;45(11):1799-806. Epub 2020/04/09. doi: 10.1038/s41386610 020-0667-2. PMID: 32268347.

611 34. Larsen C, Shahinas J. Dosage, Efficacy and Safety of Cannabidiol Administration in

Adults: A Systematic Review of Human Trials. J Clin Med Res. 2020;12(3):129-41. Epub

613 2020/04/02. doi: 10.14740/jocmr4090. PMID: 32231748.

614 35. Reuveni N, Carlson CA, Schwartz S, Meter D, Barrett TS, Freeman SM. The

antidepressant and anxiolytic effects of cannabinoids in chronic unpredictable stress: a

616 preclinical systematic review and meta-analysis. Transl Psychiatry. 2022;12(1):217. Epub

617 2022/06/01. doi: 10.1038/s41398-022-01967-1. PMID: 35641487.

618 36. Graczyk M, Lewandowska AA, Dzierżanowski T. The Therapeutic Potential of

Cannabis in Counteracting Oxidative Stress and Inflammation. Molecules. 2021;26(15). doi:
10.3390/molecules26154551. PMID: 34361704.

621 37. Soliman N, Haroutounian S, Hohmann AG, Krane E, Liao J, Macleod M, et al.

622 Systematic review and meta-analysis of cannabinoids, cannabis-based medicines, and

endocannabinoid system modulators tested for antinociceptive effects in animal models of

624 injury-related or pathological persistent pain. Pain. 2021;162(Suppl 1):S26-s44. doi:

625 10.1097/j.pain.00000000002269. PMID: 33729209.

626 38. Zavala-Tecuapetla C, Luna-Munguia H, López-Meraz ML, Cuellar-Herrera M.

627 Advances and Challenges of Cannabidiol as an Anti-Seizure Strategy: Preclinical Evidence.

628 Int J Mol Sci. 2022;23(24). doi: 10.3390/ijms232416181. PMID: 36555823.

629 39. Esposito G, Pesce M, Seguella L, Sanseverino W, Lu J, Corpetti C, et al. The

potential of cannabidiol in the COVID-19 pandemic. Br J Pharmacol. 2020;177(21):4967-70.

631 doi: 10.1111/bph.15157. PMID: 32519753.

40. Tadijan A, Vlašić I, Vlainić J, Đikić D, Oršolić N, Jazvinšćak Jembrek M.

633 Intracellular Molecular Targets and Signaling Pathways Involved in Antioxidative and

634 Neuroprotective Effects of Cannabinoids in Neurodegenerative Conditions. Antioxidants

635 [Internet]. 2022; 11(10).

41. Stohs SJ, Ray SD. Is cannabidiol hepatotoxic or hepatoprotective: A review. Toxicol
Res Appl. 2020;4:2397847320922944. doi: 10.1177/2397847320922944.

42. Russo EB. The Case for the Entourage Effect and Conventional Breeding of Clinical
Cannabis: No "Strain," No Gain. Front Plant Sci. 2018;9:1969. doi: 10.3389/fpls.2018.01969.
PMID: 30687364.

43. Russo EB, McPartland JM. Cannabis is more than simply delta(9)-

tetrahydrocannabinol. Psychopharmacology (Berl). 2003;165(4):431-2; author reply 3-4. doi:

643 10.1007/s00213-002-1348-z. PMID: 12491031.

644 44. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, et al. An entourage

effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol

646 cannabinoid activity. Eur J Pharmacol. 1998;353(1):23-31. doi: 10.1016/s0014-

647 2999(98)00392-6. PMID: 9721036.

45. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT.

649 Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the

efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with

651 intractable cancer-related pain. J Pain Symptom Manage. 2010;39(2):167-79. Epub

652 2009/11/10. doi: 10.1016/j.jpainsymman.2009.06.008. PMID: 19896326.

46. Pamplona FA, da Silva LR, Coan AC. Potential Clinical Benefits of CBD-Rich
Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data
Meta-analysis. Front Neurol. 2018;9:759. Epub 2018/09/28. doi: 10.3389/fneur.2018.00759.
PMID: 30258398.

47. Shalev N, Kendall M, Anil SM, Tiwari S, Peeri H, Kumar N, et al. Phytocannabinoid
Compositions from Cannabis Act Synergistically with PARP1 Inhibitor against Ovarian
Cancer Cells In Vitro and Affect the Wnt Signaling Pathway. Molecules. 2022;27(21). Epub
2022/11/12. doi: 10.3390/molecules27217523. PMID: 36364346.

48. Anis O, Vinayaka AC, Shalev N, Namdar D, Nadarajan S, Anil SM, et al. CannabisDerived Compounds Cannabichromene and Δ9-Tetrahydrocannabinol Interact and Exhibit
Cytotoxic Activity against Urothelial Cell Carcinoma Correlated with Inhibition of Cell
Migration and Cytoskeleton Organization. Molecules. 2021;26(2). Epub 2021/01/23. doi:
10.3390/molecules26020465. PMID: 33477303.

Blasco-Benito S, Seijo-Vila M, Caro-Villalobos M, Tundidor I, Andradas C, GarcíaTaboada E, et al. Appraising the "entourage effect": Antitumor action of a pure cannabinoid
versus a botanical drug preparation in preclinical models of breast cancer. Biochem
Pharmacol. 2018;157:285-93. Epub 2018/06/26. doi: 10.1016/j.bcp.2018.06.025. PMID:
29940172.

50. Bonn-Miller MO, ElSohly MA, Loflin MJE, Chandra S, Vandrey R. Cannabis and
cannabinoid drug development: evaluating botanical versus single molecule approaches. Int

673 Rev Psychiatry. 2018;30(3):277-84. doi: 10.1080/09540261.2018.1474730. PMID:
674 30179534.

675 51. Rice LJ, Cannon L, Dadlani N, Cheung MMY, Einfeld SL, Efron D, et al. Efficacy of
676 cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and
677 adolescents: a systematic review. European Child & Adolescent Psychiatry. 2023:1-22.

52. Aran A, Cassuto H, Lubotzky A, Wattad N, Hazan E. Brief report: cannabidiol-rich
cannabis in children with autism spectrum disorder and severe behavioral problems—a
retrospective feasibility study. Journal of Autism and Developmental Disorders.
2019;49(3):1284-8.

53. Barchel D, Stolar O, De-Haan T, Ziv-Baran T, Saban N, Fuchs DO, et al. Oral
Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms
and Co-morbidities. Front Pharmacol. 2019;9:1521. doi: 10.3389/fphar.2018.01521. PMID:
30687090.

54. Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V. Real life
experience of medical cannabis treatment in autism: analysis of safety and efficacy. Scientific
reports. 2019;9(1):1-7.

55. Fleury-Teixeira P, Caixeta FV, Ramires da Silva LC, Brasil-Neto JP, Malcher-Lopes

690 R. Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder

691 Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use.

692 Front Neurol. 2019;10:1145. Epub 2019/11/19. doi: 10.3389/fneur.2019.01145. PMID:

693 31736860.

56. Bilge S, Ekici B. CBD-enriched cannabis for autism spectrum disorder: an experience 694 of a single center in Turkey and reviews of the literature. J Cannabis Res. 2021;3(1):53. Epub 695 2021/12/17. doi: 10.1186/s42238-021-00108-7. PMID: 34911567. 696

Hacohen M, Stolar OE, Berkovitch M, Elkana O, Kohn E, Hazan A, et al. Children 57. 697 and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements

particularly in social symptoms: an open label study. Translational Psychiatry. 699

2022;12(1):375. 700

Aran A, Harel M, Cassuto H, Polyansky L, Schnapp A, Wattad N, et al. Cannabinoid 701 58.

treatment for autism: a proof-of-concept randomized trial. Molecular autism. 2021;12(1):1-702

11. 703

698

59. da Silva Junior EA, Medeiros WMB, Dos Santos JPM, de Sousa JMM, da Costa FB, 704 Pontes KM, et al. Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in 705 706 children with autism spectrum disorder: randomized, double-blind and controlled placebo

clinical trial. Trends in Psychiatry and Psychotherapy. 2022;(AheadOfPrint):0-. 707

708 60. Schnapp A, Harel M, Cavam-Rand D, Cassuto H, Polyansky L, Aran A, A Placebo-

Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and 709

Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by 710

the CSHQ. Biomedicines. 2022;10(7):1685. 711

Lord C, Rutter M, DiLavore P, Risi S, Gotham K, Bishop S, et al. Autism Diagnostic 61. 712 Observation Schedule: ADOS-2| Pearson Assessment. Pearson.; 2012. 713

62. Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, et al. Efficacy 714 and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis. Drugs. 715

2018;78(17):1791-804. Epub 2018/11/06. doi: 10.1007/s40265-018-0992-5. PMID:
30390221.

63. Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, et al. Evidence for
cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational
evidence. J Neurol Neurosurg Psychiatry. 2018;89(7):741-53. Epub 2018/03/08. doi:

721 10.1136/jnnp-2017-317168. PMID: 29511052.

64. Devinsky O, Cross JH, Wright S. Trial of Cannabidiol for Drug-Resistant Seizures in
the Dravet Syndrome. N Engl J Med. 2017;377(7):699-700. doi: 10.1056/NEJMc1708349.
PMID: 28813226.

Busner J, Targum SD. The clinical global impressions scale: applying a research tool
in clinical practice. Psychiatry (Edgmont). 2007;4(7):28-37. PMID: 20526405.

Rodgers J, Wigham S, McConachie H, Freeston M, Honey E, Parr JR. Development
of the anxiety scale for children with autism spectrum disorder (ASC-ASD). Autism Res.
2016;9(11):1205-15.

67. Bruni O, Ottaviano S, Guidetti V, Romoli M, Innocenzi M, Cortesi F, et al. The Sleep
Disturbance Scale for Children (SDSC). Construction and validation of an instrument to
evaluate sleep disturbances in childhood and adolescence. J Sleep Res. 1996;5(4):251-61.
doi: 10.1111/j.1365-2869.1996.00251.x. PMID: 9065877.

68. Efron D, Freeman JL, Cranswick N, Payne JM, Mulraney M, Prakash C, et al. A pilot

randomised placebo-controlled trial of cannabidiol to reduce severe behavioural problems in

children and adolescents with intellectual disability. British Journal of Clinical

737 Pharmacology. 2021;87(2):436-46.

69. Chen H, Yang T, Chen J, Chen L, Dai Y, Zhang J, et al. Sleep problems in children
with autism spectrum disorder: a multicenter survey. BMC Psychiatry. 2021;21(1):406. Epub
2021/08/18. doi: 10.1186/s12888-021-03405-w. PMID: 34399715.

741 70. Malow BA, Katz T, Reynolds AM, Shui A, Carno M, Connolly HV, et al. Sleep

742 Difficulties and Medications in Children With Autism Spectrum Disorders: A Registry Study.

743 Pediatrics. 2016;137 Suppl 2:S98-s104. Epub 2016/02/26. doi: 10.1542/peds.2015-2851H.

744 PMID: 26908483.

745 71. Stolar O, Hazan A, Vissoker RE, Kishk IA, Barchel D, Lezinger M, et al. Medical

cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder:

An interim analysis of biochemical safety. Front Pharmacol. 2022;13:977484. Epub

748 2022/10/18. doi: 10.3389/fphar.2022.977484. PMID: 36249785.

749 72. Silva EADJ, Medeiros WMB, Torro N, Sousa JMM, Almeida I, Costa FBD, et al.
750 Cannabis and cannabinoid use in autism spectrum disorder: a systematic review. Trends
751 Psychiatry Psychother. 2022;44:e20200149. Epub 2021/05/28. doi: 10.47626/2237-6089752 2020-0149. PMID: 34043900.

753 73. Kalvin CB, Marsh CL, Ibrahim K, Gladstone TR, Woodward D, Grantz H, et al.
754 Discrepancies between parent and child ratings of anxiety in children with autism spectrum
755 disorder. Autism Res. 2020;13(1):93-103. Epub 2019/10/24. doi: 10.1002/aur.2220. PMID:

31643143.


757

758 Figure Legend

759 Fig 1. Clinical Global Impression – Global Improvement.

760 Fig 2. Clinical Global Impression – Severity of Illness.

761 Fig 3. Clinical Global Impression - Therapeutic Effect after 28 days of treatment.



Global Improvement Rating

Figure

GLOBAL IMPROVEMENT RATINGS


1. Very much improved

2. Much improved


3. Minimally improved

4. No change

Figure



Therapeutic Effect



Figure